Journal: Frontiers in Endocrinology
Article Title: Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease
doi: 10.3389/fendo.2026.1791283
Figure Lengend Snippet: TrkA inhibition reduces the levels of p-TrkA, p-ERK, EGR1, p35, and CDK5 in the kidneys of db/db mice. (A–C) Representative western blots show the protein expression levels of (A) TrkA and phospho-TrkA (Tyr490), (B) ERK, p-ERK and EGR1, and (C) p35 and CDK5 in the kidney samples from the control, db/db, Inh-NC, and Inh-TrkA groups of mice. (D) Representative IF images show the expression of Synaptopodin (red) in the glomeruli of control, db/db, Inh-NC, and Inh-TrkA groups of mice (400X). ***p < 0.001. p < 0.05 was considered statistically significant; ns indicates not significant.
Article Snippet: Anti-phospho-TrkA (pTyr490) antibody (Cat. No. RA18018-100) was purchased from Origene (Rockville, MD, USA).
Techniques: Inhibition, Western Blot, Expressing, Control